Related Experiment Video

Updated: May 21, 2026

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

Budesonide inhibits interleukin-32 expression in a rat model of chronic obstructive pulmonary disease

Xingqi Deng1, Zhifeng Zhang, Wei Gu

  • 1Department of Emergency Medicine, Central Hospital of Minhang District, Shanghai Ruijin Hospital Group, Shanghai, China. dengchengsheng@sina.com

Experimental Lung Research
|June 1, 2012
PubMed

Insights

This study reveals budesonide inhibits interleukin-32 (IL-32) in rat lungs affected by chronic obstructive pulmonary disease (COPD). While not repairing lung damage, budesonide partly recovered pulmonary function in COPD rats.

Area of Science:

  • Pulmonary Medicine
  • Inflammation Research

Background:

  • Chronic obstructive pulmonary disease (COPD) is a major global health issue.
  • Interleukin-32 (IL-32) is implicated as a risk factor in COPD development.
  • Budesonide is a common anti-inflammatory treatment for COPD, but its precise mechanism is unclear.

Purpose of the Study:

  • To investigate the effect of budesonide on IL-32 expression in a rat model of COPD.
  • To explore the anti-inflammatory mechanism of budesonide in relation to IL-32.

Main Methods:

  • A rat model of COPD was established using cigarette smoke (CS).
  • The expression of IL-32 in lung tissue was measured.
  • Pulmonary function and lung tissue damage were assessed.
  • Budesonide treatment was administered to assess its effects.

Main Results:

  • Cigarette smoking significantly increased IL-32 expression, impaired lung function, and caused pulmonary tissue damage.
  • Budesonide treatment inhibited IL-32 expression in the lung tissue of COPD rats.
  • Budesonide did not repair lung tissue damage but led to partial recovery of pulmonary function.

Conclusions:

  • Budesonide effectively inhibits cigarette smoke-induced IL-32 expression in COPD rat lungs.
  • This study provides novel insights into the anti-inflammatory effects of budesonide, linking it to IL-32 inhibition.
  • While budesonide improves lung function, further research is needed to address tissue repair in COPD.

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...